

PEER-REVIEW REPORT

Name of journal: *World Journal of Gastroenterology*

Manuscript NO: 76810

Title: Effective combinations of anti-cancer and targeted drugs for pancreatic cancer treatment

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05698055

Position: Peer Reviewer

Academic degree: PhD

Professional title: Professor

Reviewer's Country/Territory: China

Author's Country/Territory: Japan

Manuscript submission date: 2022-04-01

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-04-12 14:28

Reviewer performed review: 2022-04-20 08:57

Review time: 7 Days and 18 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
<https://www.wjgnet.com>

Peer-reviewer statements	Peer-Review: [<input checked="" type="radio"/>] Anonymous [<input type="radio"/>] Onymous Conflicts-of-Interest: [<input type="radio"/>] Yes [<input checked="" type="radio"/>] No
-------------------------------------	---

SPECIFIC COMMENTS TO AUTHORS

Pancreatic cancer (PC) is one of the most common malignancies of the digestive tract worldwide, with increased morbidity and mortality. This review describes the combinations of gemcitabine and targeted drugs and the varieties of targeted drugs other than gemcitabine provides a comprehensive view of therapies in pancreatic cancer. However, the whole review still needs to be organized more concisely. The article is currently a simple summary of tons of work. Several important sections that should be mentioned such as clinical research and natural product research were missing. Critical points for lots of work were not extracted and organized well.

PEER-REVIEW REPORT

Name of journal: *World Journal of Gastroenterology*

Manuscript NO: 76810

Title: Effective combinations of anti-cancer and targeted drugs for pancreatic cancer treatment

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05752663

Position: Peer Reviewer

Academic degree: MD, MSc

Professional title: Associate Professor

Reviewer's Country/Territory: South Korea

Author's Country/Territory: Japan

Manuscript submission date: 2022-04-01

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-04-26 19:25

Reviewer performed review: 2022-05-04 05:06

Review time: 7 Days and 9 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
<https://www.wjgnet.com>

**Peer-reviewer
statements**

Peer-Review: [☐] Anonymous [☒] Onymous
Conflicts-of-Interest: [☐] Yes [☒] No

SPECIFIC COMMENTS TO AUTHORS

This mini-review articles give us comprehensive and well-organised information regarding gemcitabine-induced DNA damage response, and downstream signaling pathway, and the combinations of gemcitabine and targeted drugs. Thus, it will be of very interest to the readership. Thank you.